Differential Kat3 Coactivator Usage Regulates Brain Metabolism and Neuronal Differentiation.
Erasmus Kofi PokuMasaya OnoYusuke HiguchiJunie CheaElizabeth MelendezJia-Ling TeoCu NguyenNyam-Osor ChimgeMichael KahnPublished in: Current molecular pharmacology (2023)
Rebalancing the equilibrium between CBP/β-catenin versus p300/β-catenin associated transcription, utilizing the small molecule CBP/beta-catenin antagonist ICG-001, enhances mitochondrial oxidative phosphorylation, metabolic function, and neuronal differentiation and may be able to ameliorate the cognitive decline seen in neurodegenerative disorders, including Alzheimer's Disease.
Keyphrases
- cognitive decline
- small molecule
- epithelial mesenchymal transition
- mild cognitive impairment
- cell proliferation
- cerebral ischemia
- oxidative stress
- white matter
- molecular dynamics
- transcription factor
- resting state
- molecular dynamics simulations
- blood brain barrier
- multiple sclerosis
- subarachnoid hemorrhage
- brain injury